Impact of different postoperative adjuvant therapies on the survival of early-stage cervical cancer patients with one intermediate-risk factor: A multicenter study of 14 years

被引:7
|
作者
Ye, Yanna [1 ,2 ]
Li, Zhiqiang [1 ]
Kang, Shan [3 ]
Zhan, Xuemei [4 ]
Zhang, Yi [5 ]
Xu, Yan [6 ]
Li, Weili [2 ]
Lang, Jinghe [2 ,7 ]
Liu, Ping [2 ]
Chen, Chunlin [1 ,2 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, 1838 Guangzhou Ave, Guangzhou 510515, Peoples R China
[2] Dongguan Polytech, Fac Hlth, Dept Midwifery, Dongguan, Peoples R China
[3] Hebei Med Univ, Hosp 4, Dept Gynecol, Shijiazhuang, Peoples R China
[4] SEN Univ, Affiliated Jiangmen Hosp SUN YAT, Dept Obstet & Gynecol, Jiangmen, Peoples R China
[5] China Med Univ, Dept Gynecol, Hosp 1, Shenyang, Peoples R China
[6] Pan Yu Cent Hosp, Dept Obstet & Gynecol, Guangzhou, Peoples R China
[7] Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
cervical cancer; disease-free survival; intermediate-risk pathological factor; oncological outcome; overall survival; postoperative adjuvant therapy; RADICAL HYSTERECTOMY; PELVIC IRRADIATION; RADIATION-THERAPY; RANDOMIZED-TRIAL; CARCINOMA; CHEMOTHERAPY; IB; RADIOTHERAPY; CISPLATIN; METASTASIS;
D O I
10.1111/jog.15632
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare survival outcomes of different postoperative adjuvant therapies (PATs) for early-stage cervical cancer (ECC) patients with one intermediate-risk pathological factor (IPF).Methods: A total of 2889 patients with stage IA1 to IIA2 cervical cancer were included in this study. Three PAT groups were identified, namely a no adjuvant therapy (NAT) group (n = 773), an adjuvant radiotherapy/chemoradiotherapy (ART) group (n = 1648) and an adjuvant chemotherapy (ACT) group (n = 468). Kaplan-Meier analysis and COX regression analysis were used to compare the overall survival (OS) and disease-free survival (DFS) among the three groups, before and after propensity score matching (PSM).Results: The recurrence and mortality rate rates in the NAT, ART and ACT groups were 9.2%, 8.6%, and 7.9%, respectively (p = 0.737). Kaplan-Meier analysis demonstrated no significant differences in the NAT, ART, and ACT groups in 5-year OS rates (92.8% vs. 93.6% vs. 94.7%, p = 0.594) and DFS rates (88.7% vs. 89.6% vs. 90.5%, p = 0.772). Post-hoc tests yielded similar results, with no differences in 5-year OS and DFS (NAT vs. ART, before and after matching, p > 0.05); (NAT vs. ACT, before and after matching, p > 0.05); and (ACT vs. ART, before and after matching, p > 0.05).Conclusion: Postoperative adjuvant radiotherapy, chemoradiotherapy, and chemotherapy are not associated with survival outcomes of ECC patients with one IPF. Considering the side effects and impact on patients' quality of life, the PATs should be carefully considered.
引用
收藏
页码:1579 / 1591
页数:13
相关论文
共 50 条
  • [41] CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16)
    Cibula, David
    Borcinova, Martina
    Kocian, Roman
    Feltl, David
    Argalacsova, Sona
    Dvorak, Pavel
    Fischerova, Daniela
    Dundr, Pavel
    Jarkovsky, Jiri
    Hoschlova, Eva
    Slama, Jiri
    Scambia, Giovanni
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (10) : 1327 - 1331
  • [42] Impact of the Addition of Concurrent Chemotherapy to Pelvic Radiotherapy in Surgically Treated Stage IB1-IIB Cervical Cancer Patients With Intermediate-Risk or High-Risk Factors A 13-Year Experience
    Okazawa, Mika
    Mabuchi, Seiji
    Isohashi, Fumiaki
    Suzuki, Osamu
    Yoshioka, Yasuo
    Sasano, Tomoyuki
    Ohta, Yukinobu
    Kamiura, Shoji
    Ogawa, Kazuhiko
    Kimura, Tadashi
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (03) : 567 - 575
  • [43] Safe Criteria for Less Radical Trachelectomy in Patients with Early-Stage Cervical Cancer: A Multicenter Clinicopathologic Study
    Kim, Hee Seung
    Choi, Chel Hun
    Lim, Myong-Chul
    Chang, Suk-Joon
    Kim, Yong Beom
    Kim, Min A.
    Kim, Tae-Jin
    Park, Sang-Yoon
    Kim, Byoung-Gie
    Song, Yong Sang
    Bae, Duk-Soo
    Kim, Jae Weon
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (06) : 1973 - 1979
  • [45] Postoperative adjuvant therapy for stage IA-IIA cervical adenocarcinoma (FIGO 2018) with one intermediate-risk factor: a multicentre retrospective cohort study of 63,926 cases
    Fu, Jiaxin
    Liang, Cong
    Sun, Lixin
    Zhao, Hongwei
    Cui, Zhumei
    Lang, Jinghe
    Chen, Chunlin
    Liu, Ping
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2025, 23 (01)
  • [46] Impact of the Ratio of Metastatic to Examined Lymph Nodes on the Survival of Early-Stage Cervical Cancer Patients
    Metindir, Jale
    Bilir, Guelay
    ONKOLOGIE, 2009, 32 (03): : 103 - 106
  • [47] Early-stage intermediate-risk-the group with the most heterogenous management among patients with cervical cancer
    Cibula, David
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (10) : 1227 - 1228
  • [48] Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy
    Murakami, Naoya
    Asami, Yuka
    Yoshida, Hiroshi
    Takayanagi, Daisuke
    Hirose, Sou
    Kuno, Ikumi
    Takahashi, Kazuaki
    Matsuda, Maiko
    Shimada, Yoko
    Yamano, Shotaro
    Sunami, Kuniko
    Honda, Takayuki
    Nakahara, Tomomi
    Watanabe, Tomoko
    Okuma, Kae
    Kuroda, Takafumi
    Kohno, Takashi
    Kato, Tomoyasu
    Shiraishi, Kouya
    Itami, Jun
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [49] High- or Intermediate-Risk Histologic Features in Patients with Clinical Early-Stage Cervical Cancer Planned for Fertility-Sparing Surgery: A Systematic Review
    Wolswinkel, Janneke T.
    ten Eikelder, Mieke L. G.
    Verhoef, Cornelia G.
    Zusterzeel, Petra L. M.
    CANCERS, 2023, 15 (15)
  • [50] Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study
    Tantari, Matteo
    Bogliolo, Stefano
    Morotti, Matteo
    Balaya, Vincent
    Bouttitie, Florent
    Buenerd, Annie
    Magaud, Laurent
    Lecuru, Fabrice
    Guani, Benedetta
    Mathevet, Patrice
    CANCERS, 2022, 14 (01)